Strategies to Overcome Hurdles in Cancer Immunotherapy.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Cancer immunotherapy has advanced significantly but requires more effective human treatments.
• Tumors employ complex immune evasion mechanisms that necessitate novel therapeutic strategies.

Purpose of the Study:

• To review innovative technologies for overcoming challenges in cancer immunotherapy.
• To explore strategies targeting tumor-immune interactions and the tumor microenvironment.

Main Methods:

• Review of emerging technologies: multi-specific antibodies, chimeric antigen receptor (CAR) T cells, myeloid cell modulation, cancer-associated fibroblast targeting, artificial intelligence (AI)-predicted neoantigens, autologous vaccines, and mRNA vaccines.
• Analysis of how these technologies address tumor immune evasion and enhance anti-cancer immune responses.

Main Results:

• Multi-specific antibodies and CAR T cells improve tumor cell engagement and immune-mediated destruction.
• Targeting myeloid cells and cancer-associated fibroblasts modifies the immunosuppressive tumor microenvironment.
• AI-predicted neoantigens facilitate rapid identification of targets for personalized vaccines.
• Autologous and mRNA vaccines stimulate sustained immune responses against cancer neoantigens.

Conclusions:

• These diverse strategies collectively enhance cancer immunotherapy efficacy.
• The integration of these innovative approaches promises new therapeutic horizons in cancer treatment.